Literature DB >> 32914967

Chemical Strategies to Boost Cancer Vaccines.

Wen-Hao Li1, Yan-Mei Li1,2,3.   

Abstract

Personalized cancer vaccines (PCVs) are reinvigorating vaccine strategies in cancer immunotherapy. In contrast to adoptive T-cell therapy and checkpoint blockade, the PCV strategy modulates the innate and adaptive immune systems with broader activation to redeploy antitumor immunity with individualized tumor-specific antigens (neoantigens). Following a sequential scheme of tumor biopsy, mutation analysis, and epitope prediction, the administration of neoantigens with synthetic long peptide (SLP) or mRNA formulations dramatically improves the population and activity of antigen-specific CD4+ and CD8+ T cells. Despite the promising prospect of PCVs, there is still great potential for optimizing prevaccination procedures and vaccine potency. In particular, the arduous development of tumor-associated antigen (TAA)-based vaccines provides valuable experience and rational principles for augmenting vaccine potency which is expected to advance PCV through the design of adjuvants, delivery systems, and immunosuppressive tumor microenvironment (TME) reversion since current personalized vaccination simply admixes antigens with adjuvants. Considering the broader application of TAA-based vaccine design, these two strategies complement each other and can lead to both personalized and universal therapeutic methods. Chemical strategies provide vast opportunities for (1) exploring novel adjuvants, including synthetic molecules and materials with optimizable activity, (2) constructing efficient and precise delivery systems to avoid systemic diffusion, improve biosafety, target secondary lymphoid organs, and enhance antigen presentation, and (3) combining bioengineering methods to innovate improvements in conventional vaccination, "smartly" re-educate the TME, and modulate antitumor immunity. As chemical strategies have proven versatility, reliability, and universality in the design of T cell- and B cell-based antitumor vaccines, the union of such numerous chemical methods in vaccine construction is expected to provide new vigor and vitality in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32914967     DOI: 10.1021/acs.chemrev.9b00833

Source DB:  PubMed          Journal:  Chem Rev        ISSN: 0009-2665            Impact factor:   60.622


  15 in total

Review 1.  Recent Progress on Therapeutic Vaccines for Breast Cancer.

Authors:  Lianru Zhang; Xipeng Zhou; Huizi Sha; Li Xie; Baorui Liu
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

Review 2.  Peptides for Vaccine Development.

Authors:  Ian W Hamley
Journal:  ACS Appl Bio Mater       Date:  2022-02-23

3.  Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.

Authors:  Xing Huang; Tianyu Tang; Gang Zhang; Tingbo Liang
Journal:  Mol Cancer       Date:  2021-03-08       Impact factor: 27.401

Review 4.  Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development.

Authors:  Jie Liang; Xiao Zhao
Journal:  Cancer Biol Med       Date:  2021-05-12       Impact factor: 4.248

5.  Design, synthesis, and initial immunological evaluation of glycoconjugates based on saponin adjuvants and the Tn antigen.

Authors:  Roberto Fuentes; Leire Aguinagalde; Nagore Sacristán; Alberto Fernández-Tejada
Journal:  Chem Commun (Camb)       Date:  2021-10-28       Impact factor: 6.222

6.  A chitosan-mediated inhalable nanovaccine against SARS-CoV-2.

Authors:  Shao-Hua Zhuo; Jun-Jun Wu; Lang Zhao; Wen-Hao Li; Yu-Fen Zhao; Yan-Mei Li
Journal:  Nano Res       Date:  2022-02-02       Impact factor: 10.269

7.  MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide.

Authors:  Jing-Jing Du; Shi-Hao Zhou; Zi-Ru Cheng; Wen-Bo Xu; Ru-Yan Zhang; Long-Sheng Wang; Jun Guo
Journal:  Front Chem       Date:  2022-02-04       Impact factor: 5.221

8.  Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment.

Authors:  Bo Deng; Bing Ma; Yingying Ma; Pei Cao; Xigang Leng; Pengyu Huang; Yuanyuan Zhao; Tianjiao Ji; Xueguang Lu; Lanxia Liu
Journal:  J Nanobiotechnology       Date:  2022-03-18       Impact factor: 10.435

9.  Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine.

Authors:  Shi-Hao Zhou; Yu-Ting Li; Ru-Yan Zhang; Yan-Ling Liu; Zi-Wei You; Miao-Miao Bian; Yu Wen; Jian Wang; Jing-Jing Du; Jun Guo
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

10.  STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation.

Authors:  Bo-Dou Zhang; Jun-Jun Wu; Wen-Hao Li; Hong-Guo Hu; Lang Zhao; Pei-Yang He; Yu-Fen Zhao; Yan-Mei Li
Journal:  Nano Res       Date:  2022-04-18       Impact factor: 10.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.